Kyinno

Provider of engineered cell lines for the discovery of oncology drugs

placeBeijing, Beijing, China calendar_todayFounded 2017 groups65 employees language kyinno.com

Social engagement

Social engagement: 2.5K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

11 investors on record; lead investors include Matrix Partners China.

Investor typeCountShare
Venture capital655%
Private equity19%
Other / undisclosed436%

Recent activity

25 Jun 2026
Product launch
FUT8 knockout platform based on engineered CHO cell lines including CHOK1-FUT8-KO, CHOK1-GS-KO, and CHOK1-GS/FUT8 double knockout models
Coming soon